Skip to content

Released Feb 3, 2026, before the open

10-K filed Feb 26, 2026, 57 days after period end · 0000078003-26-000026

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$17.56Bderived−1.2% vs Q4 2024+5.4% vs Q3 2025
Net Income-$1.65BderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$5,348,000,000−20.4%
Free Cash Flowderived$4,503,000,000−22.4%
Margins · derived
Net margin-9.4%−11.7 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$17.56B$17.76B$5.93B$15.75B
Net Income-$1.65B$410.00M-$3.37B$4.99B

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR